150 Quek and associates151 reported seven previously healthy patients who developed depression within 6 months of starting treatment with imatinib

and dasatinib; in all cases, symptoms improved after dose reduction and discontinuation of the drug. In two of these cases, symptoms reappeared after a drug rechallenge. Similarly, depressed mood is listed as an adverse reaction in the prescribing information for cetuximab, dasatinib, sorafenib, and sunitinib; meta-analysis of clinical trials and literature reviews of these agents do not report any data on the Inhibitors,research,lifescience,medical statistically significant occurrence of depressive symptoms. Finally, using a standardized tool, Pirl and associates152 failed to find a statistically significant association between Inhibitors,research,lifescience,medical depressive symptoms and concomitant use of gefitinib or erlotinib. Hormonal agents Estrogen and testosterone deficiencies have been linked to MDD. Presumed mechanisms include alteration of the concentration

and availability of http://www.selleckchem.com/products/Gefitinib.html neurotransmitters amines, including serotonin. Treatment of hormone-sensitive tumors involves use of medications aimed at reducing availability of sex hormones. Studies evaluating the association between depression and treatment with tamoxifen have yielded diverse results. Inhibitors,research,lifescience,medical In some trials, a subset of patients have discontinued tamoxifen therapy because of depressive symptoms, whereas in other studies, conducted primarily in the breast cancer prevention setting, no increased risk of depression was observed during treatment.153 Similarly, studies on aromatase inhibitors have yielded mixed results. A large clinical trial involving 9366 postmenopausal women with localized breast cancer compared anastrozole and tamoxifen; they reported depressive symptoms Inhibitors,research,lifescience,medical occurring in 19.3% of patients treated with anastrozole.154 However, subsequent studies have not replicated these findings. Finally, gonadotropin releasing hormone (GnRH) agonists (ie, leuprolide Inhibitors,research,lifescience,medical and goserelin), have been associated with depression in noncancer populations. Clinical trials in prostate cancer patients have showed diverse results, AV-951 and well-controlled

prospective studies have suggested that depression occurs, although fatigue is more prevalent and may be mistaken for depression.155 Miscellaneous medications selleck kinase inhibitor isotretinoin Patients with acne are at an increased risk for depression, with prevalence rates of up to 30% reported in patients who suffer from moderate to severe acne.156 One of the most effective treatments for nodulocystic acne, isotretinoin (a synthetic oral retinoid medication), became a source of significant concern due to its potential link with the development of depressive symptoms. Evidence for concerns about depressive symptoms and suicidal ideation came primarily from case reports and case series.157 More recently, however, these claims have been challenged by the results of both retrospective and prospective trials.